(RTTNews) - Monte Rosa Therapeutics, Inc. (GLUE) today will present updated interim results from its ongoing Phase 1/2 study of MRT-2359 in patients with metastatic castration-resistant prostate ...
Shares of Monte Rosa Therapeutics, Inc. (GLUE) surged after the company reported positive interim phase 1 results of MRT-8102, its wholly owned NEK7 molecular glue degrader. We saw significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results